Targeted Delivery Advantage Leverage RenovoRx's TAMP platform and RenovoCath for localized, arterial-wall drug delivery near tumors to position as a safer, tolerable alternative to systemic chemotherapy, appealing to oncology centers aiming to reduce treatment-related toxicities.

Phase III Candidate IAG in the TIGeR-PaC trial offers a potential differentiator in pancreatic cancer therapy; target collaborations with academic centers and CROs pursuing innovative intra-arterial approaches and patients eligible for enrollment in later-stage studies.

Commercial Cath Demand First commercial orders for RenovoCath indicate market receptivity among high-volume centers; expand engagement with existing customers and NC I-designated centers to drive repeat device orders and cross-sell integration with device-based delivery.

Economic Pathway Recent revenue growth and a path toward potential breakeven suggest pursuing payer and hospital value-based discussions highlighting reduced systemic toxicity, shorter admissions, and potential for favorable cost-of-care narratives to support adoption.

Strategic Partnerships Engage with leading oncology institutions, contract research firms, and device integrators to co-market IAG and RenovoCath, leverage ongoing ASCO GI and investor events for pipeline visibility, and explore companion diagnostics or imaging collaborations around TAMP-enabled therapies.